Exscientia PLCNASDAQ:EXAI
- LAST PRICE5.4495
- TODAY'S CHANGE (%)0.3495 (6.8529%)
- Bid / Lots5.4400/ 3
- Ask / Lots5.4500/ 1
- Open / Previous Close5.1200 / 5.1000
- Day Range
- 52 Week Range
- Volume139,433
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EXAI |
|---|---|---|
| 09:32 ET | 15297 | 5.1573 |
| 09:34 ET | 100 | 5.165 |
| 09:36 ET | 2800 | 5.16 |
| 09:38 ET | 800 | 5.16 |
| 09:39 ET | 100 | 5.14 |
| 09:41 ET | 3990 | 5.2 |
| 09:43 ET | 5231 | 5.2774 |
| 09:45 ET | 1065 | 5.27 |
| 09:48 ET | 500 | 5.26 |
| 09:50 ET | 350 | 5.275 |
| 09:52 ET | 2026 | 5.28 |
| 09:54 ET | 250 | 5.28 |
| 09:57 ET | 252 | 5.24 |
| 09:59 ET | 100 | 5.265 |
| 10:01 ET | 2000 | 5.3 |
| 10:03 ET | 100 | 5.32 |
| 10:06 ET | 345 | 5.32 |
| 10:08 ET | 745 | 5.325 |
| 10:10 ET | 1111 | 5.3299 |
| 10:12 ET | 600 | 5.33 |
| 10:14 ET | 300 | 5.32 |
| 10:15 ET | 1148 | 5.33 |
| 10:17 ET | 3263 | 5.37 |
| 10:19 ET | 100 | 5.355 |
| 10:21 ET | 913 | 5.3692 |
| 10:24 ET | 4985 | 5.3999 |
| 10:26 ET | 469 | 5.39 |
| 10:28 ET | 1310 | 5.38 |
| 10:30 ET | 600 | 5.3586 |
| 10:32 ET | 675 | 5.35 |
| 10:33 ET | 1750 | 5.36 |
| 10:35 ET | 800 | 5.36 |
| 10:37 ET | 3907 | 5.3863 |
| 10:39 ET | 3635 | 5.3885 |
| 10:42 ET | 2941 | 5.415 |
| 10:44 ET | 1540 | 5.42 |
| 10:46 ET | 19031 | 5.4 |
| 10:48 ET | 6568 | 5.415 |
| 10:50 ET | 345 | 5.4178 |
| 10:51 ET | 167 | 5.42 |
| 10:53 ET | 2800 | 5.41 |
| 10:55 ET | 4992 | 5.47 |
| 10:57 ET | 1066 | 5.4405 |
| 11:00 ET | 3396 | 5.4691 |
| 11:02 ET | 1611 | 5.4501 |
| 11:04 ET | 1340 | 5.46 |
| 11:06 ET | 3662 | 5.45 |
| 11:09 ET | 200 | 5.44 |
| 11:11 ET | 1570 | 5.435 |
| 11:13 ET | 1611 | 5.45 |
| 11:15 ET | 4534 | 5.45 |
| 11:18 ET | 1776 | 5.45 |
| 11:20 ET | 100 | 5.45 |
| 11:22 ET | 2076 | 5.45 |
| 11:24 ET | 660 | 5.4495 |
Jun 25, 2024
EXAI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action - EXAI, from 2:11PM ET on Tuesday Jun 25, 2024 by Dow Jones
2:11PM ET on Tuesday Jun 25, 2024 by Dow JonesExscientia plc Class Action: Levi & Korsinsky Reminds Exscientia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 - EXAI, from 11:46AM ET on Tuesday Jun 25, 2024 by Dow Jones
11:46AM ET on Tuesday Jun 25, 2024 by Dow JonesContact Levi & Korsinsky by June 25, 2024 Deadline to Join Class Action Against Exscientia plc(EXAI), from 11:46AM ET on Tuesday Jun 25, 2024 by Dow Jones
11:46AM ET on Tuesday Jun 25, 2024 by Dow JonesExscientia Plc Investors With Losses Are Encouraged By The Schall Law Firm To Start Communication Be Aware Of The Deadline In This Case, from 11:05AM ET on Tuesday Jun 25, 2024 by Dow Jones
11:05AM ET on Tuesday Jun 25, 2024 by Dow JonesShareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More, from 11:05AM ET on Tuesday Jun 25, 2024 by Dow Jones
11:05AM ET on Tuesday Jun 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Exscientia PLC | 442.3M | -4.2x | --- |
Arbutus Biopharma Corp | 590.7M | -7.2x | --- |
OmniAb Inc | 431.6M | -5.7x | --- |
Contineum Therapeutics Inc | 532.2M | 26.8x | --- |
Iteos Therapeutics Inc | 521.6M | -3.9x | --- |
PureTech Health PLC | 560.6M | -9.8x | --- |
Company Information
Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing, and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Patient-first AI, Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company’s advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
Contact Information
- Headquarters
- The Schrodinger Building Oxford Science ParkOXFORD, United Kingdom OX4 4GE
- Phone
- 186-581-8941
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Nicholson
- Interim Chief Executive Officer, Chief Scientific Officer
- David Hallett
- Chief Financial and Strategy Officer, Director
- Ben Taylor
- Chief Technology Officer
- John Overington
- Interim Chief Medical Officer
- Maria-louise Fjaellskog
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $442.3M |
|---|---|
Revenue (TTM) | $24.9M |
Shares Outstanding | 86.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.30 |
Book Value | $3.59 |
P/E Ratio | -4.2x |
Price/Sales (TTM) | 17.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -802.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
